We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adaptive Biotechnologies (ADPT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adaptive Biotechnologies is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ADPT has gained about 74.5% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Adaptive Biotechnologies is outperforming its peers so far this year.
Another stock in the Medical sector, CVS Health (CVS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 43.2%.
In CVS Health's case, the consensus EPS estimate for the current year increased 4.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 0.2% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.
CVS Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #69. The industry has moved -0.9% so far this year.
Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and CVS Health. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adaptive Biotechnologies (ADPT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adaptive Biotechnologies is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, ADPT has gained about 74.5% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Adaptive Biotechnologies is outperforming its peers so far this year.
Another stock in the Medical sector, CVS Health (CVS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 43.2%.
In CVS Health's case, the consensus EPS estimate for the current year increased 4.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 0.2% so far this year, meaning that ADPT is performing better in terms of year-to-date returns.
CVS Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #69. The industry has moved -0.9% so far this year.
Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and CVS Health. These stocks will be looking to continue their solid performance.